Lymphatic and Inflammation Research Laboratory, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile.
Departamento de Inmunología Clínica y Reumatología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Front Immunol. 2019 Apr 15;10:772. doi: 10.3389/fimmu.2019.00772. eCollection 2019.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the presence of autoantibodies against nuclear antigens, immune complex deposition, and tissue damage in the kidneys, skin, heart and lung. Because of the pathogenic role of antinuclear antibodies and autoreactive T cells in SLE, extensive efforts have been made to demonstrate how B cells act as antibody-producing or as antigen-presenting cells that can prime autoreactive T cell activation. With the discovery of new innate immune cells and inflammatory mediators, innate immunity is emerging as a key player in disease pathologies. Recent work over the last decade has highlighted the importance of innate immune cells and molecules in promoting and potentiating SLE. In this review, we discuss recent evidence of the involvement of different innate immune cells and pathways in the pathogenesis of SLE. We also discuss new therapeutics targets directed against innate immune components as potential novel therapies in SLE.
系统性红斑狼疮（SLE）是一种慢性自身免疫性疾病，其特征是存在针对核抗原的自身抗体、免疫复合物沉积以及肾脏、皮肤、心脏和肺部的组织损伤。由于抗核抗体和自身反应性 T 细胞在 SLE 中的致病作用，人们已经做出了广泛的努力来证明 B 细胞如何作为产生抗体或作为抗原呈递细胞来激活自身反应性 T 细胞。随着新的先天免疫细胞和炎症介质的发现，先天免疫正在成为疾病病理生理学的关键因素。在过去十年的最新研究中，先天免疫细胞和分子在促进和加剧 SLE 中的重要性得到了强调。在这篇综述中，我们讨论了不同先天免疫细胞和途径参与 SLE 发病机制的最新证据。我们还讨论了针对先天免疫成分的新治疗靶点作为 SLE 潜在的新型治疗方法。
